Bowling Portfolio Management LLC bought a new stake in Medpace Holdings Inc (NASDAQ:MEDP) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 38,140 shares of the company’s stock, valued at approximately $2,285,000. Bowling Portfolio Management LLC owned 0.11% of Medpace at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. SG Americas Securities LLC acquired a new stake in shares of Medpace in the 2nd quarter valued at about $107,000. Metropolitan Life Insurance Co. NY lifted its position in Medpace by 57.1% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 4,144 shares of the company’s stock valued at $178,000 after acquiring an additional 1,507 shares in the last quarter. Sei Investments Co. lifted its position in Medpace by 5,087.5% in the 2nd quarter. Sei Investments Co. now owns 4,565 shares of the company’s stock valued at $196,000 after acquiring an additional 4,477 shares in the last quarter. CAPROCK Group Inc. bought a new position in Medpace in the 2nd quarter valued at about $223,000. Finally, Measured Wealth Private Client Group LLC bought a new position in Medpace in the 2nd quarter valued at about $223,000. Institutional investors own 40.22% of the company’s stock.
Shares of Medpace stock traded up $0.04 during mid-day trading on Friday, hitting $58.74. 629,338 shares of the stock were exchanged, compared to its average volume of 535,811. Medpace Holdings Inc has a 12 month low of $31.70 and a 12 month high of $65.09. The company has a quick ratio of 0.66, a current ratio of 0.66 and a debt-to-equity ratio of 0.25. The stock has a market cap of $2.07 billion, a P/E ratio of 38.64, a P/E/G ratio of 1.46 and a beta of 1.41.
Medpace (NASDAQ:MEDP) last posted its earnings results on Thursday, November 1st. The company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.04. Medpace had a net margin of 10.84% and a return on equity of 15.86%. The firm had revenue of $179.00 million for the quarter, compared to analysts’ expectations of $175.07 million. During the same quarter last year, the firm earned $0.40 EPS. The company’s quarterly revenue was up 44.4% compared to the same quarter last year. On average, equities analysts anticipate that Medpace Holdings Inc will post 2.5 EPS for the current year.
Several brokerages recently weighed in on MEDP. Zacks Investment Research raised shares of Medpace from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research report on Thursday, November 1st. BidaskClub cut shares of Medpace from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 31st. Credit Suisse Group raised their price target on shares of Medpace from $42.00 to $49.00 and gave the company an “outperform” rating in a research report on Tuesday, July 31st. TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a research report on Friday, August 10th. Finally, SunTrust Banks raised shares of Medpace from a “hold” rating to a “buy” rating and set a $63.00 price target on the stock in a research report on Wednesday, October 31st. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Medpace currently has a consensus rating of “Buy” and an average target price of $44.43.
In other Medpace news, major shareholder Medpace Investors, Llc sold 61,141 shares of Medpace stock in a transaction that occurred on Wednesday, September 19th. The shares were sold at an average price of $60.20, for a total transaction of $3,680,688.20. Following the transaction, the insider now owns 9,084,369 shares of the company’s stock, valued at approximately $546,879,013.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Medpace Limited Partnership sold 5,224,997 shares of Medpace stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $54.75, for a total transaction of $286,068,585.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,621,556 shares of company stock worth $309,490,974. Insiders own 29.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Equities Focus and is the sole property of of Equities Focus. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.equitiesfocus.com/2018/11/10/bowling-portfolio-management-llc-buys-shares-of-38140-medpace-holdings-inc-medp.html.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Article: Stock Symbol
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.